5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid | 107143-69-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid
• 英文别名: 5-Bromo-2-{[(4-chlorophenyl)sulfonyl]amino}benzoic acid；5-bromo-2-[(4-chlorophenyl)sulfonylamino]benzoic acid
• CAS: 107143-69-1
• 化学式: C₁₃H₉BrClNO₄S
• 分子量: 390.642
• InChiKey: JDVLYAYDIMUAAC-UHFFFAOYSA-N

物化性质

• 沸点：
  530.7±60.0 °C(Predicted)
• 密度：
  1.781±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-氯苯磺酰氯 、 2-氨基-5-溴苯甲酸 在 sodium carbonate 作用下， 以 水 为溶剂， 以92%的产率得到5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid
  参考文献：
  名称：

  Discovery of Inhibitors of Burkholderia pseudomallei Methionine Aminopeptidase with Antibacterial Activity

  摘要：

  Evaluation of a series of MetAP inhibitors in an in vitro enzyme activity assay led to the first identification of potent molecules that show significant growth inhibition against Burkholderia pseudomallei. Nitroxoline analogues show excellent inhibition potency in the BpMetAP1 enzyme activity assay with the lowest IC50 of 30 nM and inhibit the growth of B. pseudomallei and B. thailandensis at concentrations >= 31 mu M.

  DOI：

  10.1021/ml400034m

文献信息

• Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
  申请人：Wilson Ian

  公开号：US20060239915A1

  公开（公告）日：2006-10-26

  The present invention is in the field of diagnostic imaging. In one aspect, the invention relates to novel imaging agents comprising synthetic macrophage scavenger receptor A antagonists, said imaging agents being useful in the diagnostic imaging of cardiovascular disease. Also claimed in the present invention is a pharmaceutical composition comprising the novel imaging agents of the invention, said pharmaceutical composition being useful for the diagnostic imaging of cardiovascular disease in humans. Another aspect of the present invention is a kit useful in the preparation of the pharmaceutical composition of the invention. Furthermore, the use of the imaging agent of the invention for the diagnostic imaging of cardiovascular disease is also claimed.

  本发明涉及诊断成像领域。在一个方面，本发明涉及包含合成巨噬细胞清道夫受体A拮抗剂的新型成像剂，该成像剂在心血管疾病的诊断成像中有用。本发明还声明了一种制药组合物，包括本发明的新型成像剂，该制药组合物在人类心血管疾病的诊断成像中有用。本发明的另一个方面是一种用于制备本发明制药组合物的试剂盒。此外，本发明声明了使用本发明成像剂进行心血管疾病的诊断成像的用途。
• Methods of Treating an Overweight or Obese Subject
  申请人：Vath James E.

  公开号：US20120010290A1

  公开（公告）日：2012-01-12

  The invention herein generally relates to methods of treating a subject having an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the invention herein provides a method of treating a subject having overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.